Education
About Us
Working with TipRanks
Follow Us
Edgewise Therapeutics (EWTX)
NASDAQ:EWTX
Total Valuation
Edgewise Therapeutics has a market cap or net worth of $1.55B. The enterprise value is ―.
Market Cap$1.55B
Enterprise Value―
Share Statistics
Edgewise Therapeutics has 105,200,220 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding105,200,220
Owned by Insiders1.38%
Owned by Institutions74.36%
Financial Efficiency
Edgewise Therapeutics’s return on equity (ROE) is -0.29 and return on invested capital (ROIC) is -34.23%.
Return on Equity (ROE)-0.29
Return on Assets (ROA)-0.27
Return on Invested Capital (ROIC)-34.23%
Return on Capital Employed (ROCE)-0.34
Revenue Per Employee0.00
Profits Per Employee-1.14M
Employee Count117
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Edgewise Therapeutics is -18.44. Edgewise Therapeutics’s PEG ratio is -5.70.
PE Ratio-18.44
PS Ratio0.00
PB Ratio5.54
Price to Fair Value5.37
Price to FCF-23.75
Price to Operating Cash Flow-23.34
PEG Ratio-5.70
Income Statement
In the last 12 months, Edgewise Therapeutics had revenue of 0.00 and earned -133.81M in profits. Earnings per share was -1.45.
Revenue0.00
Gross Profit0.00
Operating Income-158.83M
Pretax Income-133.81M
Net Income-133.81M
EBITDA-158.83M
Earnings Per Share (EPS)-1.45
Cash Flow
In the last 12 months, operating cash flow was -109.03M and capital expenditures -1.31M, giving a free cash flow of -110.34M billion.
Operating Cash Flow-109.03M
Free Cash Flow-110.34M
Free Cash Flow per Share-1.05
Dividends & Yields
Edgewise Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta2.31
52-Week Price Change-21.26%
50-Day Moving Average17.88
200-Day Moving Average24.63
Relative Strength Index (RSI)44.01
Average Volume (3m)1.55M
Important Dates
Edgewise Therapeutics upcoming earnings date is Aug 7, 2025, TBA Not Confirmed.
Last Earnings DateMay 8, 2025
Next Earnings DateAug 7, 2025
Ex-Dividend Date―
Financial Position
Edgewise Therapeutics as a current ratio of 19.93, with Debt / Equity ratio of 1.03%
Current Ratio19.93
Quick Ratio19.93
Debt to Market Cap<0.01
Net Debt to EBITDA0.23
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Edgewise Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Edgewise Therapeutics EV to EBITDA ratio is -15.30, with an EV/FCF ratio of -22.03.
EV to Sales0.00
EV to EBITDA-15.30
EV to Free Cash Flow-22.03
EV to Operating Cash Flow-22.29
Balance Sheet
Edgewise Therapeutics has $470.17M in cash and marketable securities with $4.74M in debt, giving a net cash position of -$465.43M billion.
Cash & Marketable Securities$470.17M
Total Debt$4.74M
Net Cash-$465.43M
Net Cash Per Share-$4.42
Tangible Book Value Per Share$4.97
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Edgewise Therapeutics is $41.89, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$41.89
Price Target Upside183.42% Upside
Analyst ConsensusStrong Buy
Analyst Count9
Revenue Growth Forecast―
EPS Growth Forecast7.97%